Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Dosage Form Design for Oral Drug Delivery
share announcement

Dosage Form Design for Oral Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmaceutical Technology, Manufacturing and Devices".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 9292

Special Issue Editors

Prof. Dr. Pornsak Sriamornsak

E-Mail Website
Guest Editor
Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand
Interests: oral drug delivery; dosage form design; cancer targeting drug delivery; pharmaceutical nanotechnology; biopolymer; 3D printing
Dr. Kampanart Huanbutta

E-Mail Website
Guest Editor
School of Pharmacy, Eastern Asian University, Thanyaburi District, Pathumthani 12110, Thailand
Interests: 3D printing; pharmaceutical dosage forms for elderly; film-forming systems

Special Issue Information

Dear Colleagues,

Oral dosage forms are the gold standard for the management and/or treatment of chronic and debilitating disorders such as hypertension, hyperlipidemia, cancer, neurodegenerative and psychotropic diseases, and various infections. Patients vary in terms of age, swallowing ability, and dosage. A single dosage form or regular dosage forms may not be sufficient for all patient groups. Oral drug delivery technologies have evolved to include orodispersible tablets, gastro-retentive drug delivery, colonic drug delivery, and fixed-dose combination drug delivery. Therefore, the design of dosage forms for oral drug delivery is critical for optimizing therapeutic effects while reducing adverse effects.

The purpose of this special issue is to highlight and document the novel oral drug delivery system. For this special issue, we invite submissions on all aspects of dosage form design for oral drug delivery studies that highlight world-class research.

Prof. Dr. Pornsak Sriamornsak
Dr. Kampanart Huanbutta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oral dosage forms
  • oral drug delivery
  • dosage form design
  • novel drug delivery
  • orodispersible tablets
  • gastro-retentive drug delivery
  • colonic drug delivery
  • drug dissolution

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 4721 KiB  
Article
Development and Characterization of Pullulan-Based Orodispersible Films of Iron
by Maram Suresh Gupta, Tegginamath Pramod Kumar, Dinesh Reddy, Kamla Pathak, Devegowda Vishakante Gowda, A. V. Naresh Babu, Alhussain H. Aodah, El-Sayed Khafagy, Hadil Faris Alotaibi, Amr Selim Abu Lila, Afrasim Moin and Talib Hussin
Pharmaceutics 2023, 15(3), 1027; https://doi.org/10.3390/pharmaceutics15031027 - 22 Mar 2023
Cited by 3 | Viewed by 2133
Abstract
Iron deficiency is the principal cause of nutritional anemia and it constitutes a major health problem, especially during pregnancy. Despite the availability of various non-invasive traditional oral dosage forms such as tablets, capsules, and liquid preparations of iron, they are hard to consume [...] Read more.
Iron deficiency is the principal cause of nutritional anemia and it constitutes a major health problem, especially during pregnancy. Despite the availability of various non-invasive traditional oral dosage forms such as tablets, capsules, and liquid preparations of iron, they are hard to consume for special populations such as pregnant women, pediatric, and geriatric patients with dysphagia and vomiting tendency. The objective of the present study was to develop and characterize pullulan-based iron-loaded orodispersible films (i-ODFs). Microparticles of iron were formulated by a microencapsulation technique, to mask the bitter taste of iron, and ODFs were fabricated by a modified solvent casting method. Morphological characteristics of the microparticles were identified by optical microscopy and the percentage of iron loading was evaluated by inductively coupled plasma optical emission spectroscopy (ICP-OES). The fabricated i-ODFs were evaluated for their morphology by scanning electron microscopy. Other parameters including thickness, folding endurance, tensile strength, weight variation, disintegration time, percentage moisture loss, surface pH, and in vivo animal safety were evaluated. Lastly, stability studies were carried out at a temperature of 25 °C/60% RH. The results of the study confirmed that pullulan-based i-ODFs had good physicochemical properties, excellent disintegration time, and optimal stability at specified storage conditions. Most importantly, the i-ODFs were free from irritation when administered to the tongue as confirmed by the hamster cheek pouch model and surface pH determination. Collectively, the present study suggests that the film-forming agent, pullulan, could be successfully employed on a lab scale to formulate orodispersible films of iron. In addition, i-ODFs can be processed easily on a large scale for commercial use. Full article
(This article belongs to the Special Issue Dosage Form Design for Oral Drug Delivery)
►▼ Show Figures

Figure 1

18 pages, 1318 KiB  
Article
Development of Oral Microemulsion Spray Containing Pentacyclic Triterpenes-Rich Centella asiatica (L.) Urb. Extract for Healing Mouth Ulcers
by Vilasinee Sanguansajapong, Pajaree Sakdiset and Panupong Puttarak
Pharmaceutics 2022, 14(11), 2531; https://doi.org/10.3390/pharmaceutics14112531 - 20 Nov 2022
Cited by 2 | Viewed by 2450
Abstract
Several publications have shown that Centella asiatica (L.) Urb. and its active constituents (pentacyclic triterpenes) are effective in wound healing. The pentacyclic triterpenes-rich C. asiatica extract (PRE) was prepared following a previous study by microwave-assisted extraction (MAE) and fractionation with macroporous resin. This method [...] Read more.
Several publications have shown that Centella asiatica (L.) Urb. and its active constituents (pentacyclic triterpenes) are effective in wound healing. The pentacyclic triterpenes-rich C. asiatica extract (PRE) was prepared following a previous study by microwave-assisted extraction (MAE) and fractionation with macroporous resin. This method provided the pentacyclic triterpene content in the extract up to 59.60% w/w. The PRE showed potent anti-inflammatory activity by inhibiting nitric oxide (NO) production with an IC50 value of 20.59 ± 3.48 μg/mL and a potent fibroblast proliferative effect (165.67%) at concentrations of 10 μg/mL. The prepared microemulsion consisted of a water: oil: surfactant mixture of 2: 2: 6, using coconut oil: clove oil (1:1) as the oil phase and Tween 20: Span 20 (2:1) as the surfactant mixture and 1.0, 2.5, and 5.0% PRE. Cell proliferation, migration, and collagen production of the microemulsion base and microemulsions containing 1.0%, 2.5%, and 5.0% PRE were evaluated. The results revealed that the microemulsion containing 1% PRE had the highest proliferation effect (136.30 ± 3.93% to 152.65 ± 3.48% at concentrations of 10 μg/mL), migration activities (100.00 ± 0.0% at 24 h), and collagen production in human dermal fibroblast (HDF) and human gingival fibroblast (HGF) cells when compared with other formulations or blank. Moreover, the anti-inflammatory activity of microemulsions containing 1% PRE was slightly lower than standard indomethacin. Anti-inflammation of the microemulsion containing PRE exhibited a dose-dependent trend, while 5% PRE was more potent than the standard drug. Considering the potent wound-healing activities and the good anti-inflammatory activity of the microemulsion containing PRE, the microemulsion with 1% PRE was identified as the most suitable oral spray formulation for oral ulcer treatment. Full article
(This article belongs to the Special Issue Dosage Form Design for Oral Drug Delivery)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 1733 KiB  
Review
Practical Application of 3D Printing for Pharmaceuticals in Hospitals and Pharmacies
by Kampanart Huanbutta, Kanokporn Burapapadh, Pornsak Sriamornsak and Tanikan Sangnim
Pharmaceutics 2023, 15(7), 1877; https://doi.org/10.3390/pharmaceutics15071877 - 04 Jul 2023
Cited by 5 | Viewed by 4112
Abstract
Three-dimensional (3D) printing is an unrivaled technique that uses computer-aided design and programming to create 3D products by stacking materials on a substrate. Today, 3D printing technology is used in the whole drug development process, from preclinical research to clinical trials to frontline [...] Read more.
Three-dimensional (3D) printing is an unrivaled technique that uses computer-aided design and programming to create 3D products by stacking materials on a substrate. Today, 3D printing technology is used in the whole drug development process, from preclinical research to clinical trials to frontline medical treatment. From 2009 to 2020, the number of research articles on 3D printing in healthcare applications surged from around 10 to 2000. Three-dimensional printing technology has been applied to several kinds of drug delivery systems, such as oral controlled release systems, micropills, microchips, implants, microneedles, rapid dissolving tablets, and multiphase release dosage forms. Compared with conventional manufacturing methods of pharmaceutical products, 3D printing has many advantages, including high production rates due to the flexible operating systems and high drug loading with the desired precision and accuracy for potent drugs administered in small doses. The cost of production via 3D printing can be decreased by reducing material wastage, and the process can be adapted to multiple classes of pharmaceutically active ingredients, including those with poor solubility. Although several studies have addressed the benefits of 3D printing technology, hospitals and pharmacies have only implemented this process for a small number of practical applications. This article discusses recent 3D printing applications in hospitals and pharmacies for medicinal preparation. The article also covers the potential future applications of 3D printing in pharmaceuticals. Full article
(This article belongs to the Special Issue Dosage Form Design for Oral Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop